148 related articles for article (PubMed ID: 35450752)
1. Long-acting depot buprenorphine in people who are homeless: Views and experiences.
Matheson C; Foster R; Schofield J; Browne T
J Subst Abuse Treat; 2022 Aug; 139():108781. PubMed ID: 35450752
[TBL] [Abstract][Full Text] [Related]
2. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
3. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
4. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
5. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
6. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B; Monwell B; Capusan AJ
Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
[TBL] [Abstract][Full Text] [Related]
7. "Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED.
Schoenfeld EM; Westafer LM; Beck SA; Potee BG; Vysetty S; Simon C; Tozloski JM; Girardin AL; Soares WE
Acad Emerg Med; 2022 Aug; 29(8):928-943. PubMed ID: 35426962
[TBL] [Abstract][Full Text] [Related]
8. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
[TBL] [Abstract][Full Text] [Related]
9. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
10. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.
Seval N; Nunez J; Roth P; Schade M; Strong M; Frank CA; Litwin AH; Levin FR; Brady KT; Nunes EV; Springer SA
J Addict Med; 2023 Jul-Aug 01; 17(4):e232-e239. PubMed ID: 37579095
[TBL] [Abstract][Full Text] [Related]
11. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
12. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
Ling R; White B; Roberts J; Cretikos M; Howard MV; Haber PS; Lintzeris N; Reeves P; Dunlop AJ; Searles A
BMC Health Serv Res; 2022 Nov; 22(1):1326. PubMed ID: 36348369
[TBL] [Abstract][Full Text] [Related]
13. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
14. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
15. Low-Barrier Buprenorphine Treatment for People Experiencing Homelessness.
Gibson CL; Lo E
Psychiatr Serv; 2023 Jan; 74(1):104. PubMed ID: 36254451
[No Abstract] [Full Text] [Related]
16. Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine.
Sud A; Salamanca-Buentello F; Buchman DZ; Sabioni P; Majid U
J Subst Abuse Treat; 2022 Apr; 135():108651. PubMed ID: 34728134
[TBL] [Abstract][Full Text] [Related]
17. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
Neale J; Tompkins CNE; Strang J
Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
[TBL] [Abstract][Full Text] [Related]
18. "
Checkley L; Steiger S; Knight KR
Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
[No Abstract] [Full Text] [Related]
19. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
[TBL] [Abstract][Full Text] [Related]
20. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.
Winstock AR; Lintzeris N; Lea T
Int J Drug Policy; 2011 Jan; 22(1):77-81. PubMed ID: 20956077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
